BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/30/2021 10:10:27 AM | Browse: 398 | Download: 943
 |
Received |
|
2020-10-26 08:01 |
|
Peer-Review Started |
|
2020-10-26 08:01 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2020-11-03 00:14 |
|
Revised |
|
2020-11-12 08:48 |
|
Second Decision |
|
2020-11-17 12:42 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2020-11-21 05:41 |
|
Articles in Press |
|
2020-11-21 05:41 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-01-06 01:37 |
|
Publish the Manuscript Online |
|
2021-01-30 10:10 |
| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jonathan Wong-Chong, Maureen Bernadach, Angeline Ginzac, Hugo Veyssière and Xavier Durando |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hugo Veyssière, N/A, N/A, Division de Recherche Clinique, Délégation Recherche Clinique et Innovation, Centre Jean PERRIN, 58 rue Montalembert, Clermont-Ferrand 63011, France. hugo.veyssiere@clermont.unicancer.fr |
| Key Words |
Thymic epithelial carcinoma; Programmed death-ligand 1 negative; Pembrolizumab; Immune checkpoint; Metastasis; Case report |
| Core Tip |
Thymic epithelial carcinomas are rare and have poor prognosis. The overall 5-year survival rate for patients with thymic carcinoma is about 30%–50%. We present the case of a 45-year-old Caucasian male who presented with hepatalgia and a cervical mass, and was diagnosed with programmed death-ligand 1-negative metastatic thymic carcinoma. The patient underwent pretreatment with platinum-based chemotherapy, after which pembrolizumab was administered as salvage therapy and complete metabolic response was achieved. |
| Publish Date |
2021-01-30 10:10 |
| Citation |
Wong-Chong J, Bernadach M, Ginzac A, Veyssière H, Durando X. Pembrolizumab as a novel therapeutic option for patients with refractory thymic epithelial tumor: A case report. World J Clin Cases 2021; 9(5): 1139-1147 |
| URL |
https://www.wjgnet.com/2307-8960/full/v9/i5/1139.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v9.i5.1139 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
